Assessment of Physicochemical Properties of Rituximab Related to Its Immunomodulatory Activity

Table 2

Glycosylation microheterogeneity obtained by HILI-UPLC. Variation is presented as confidence interval at 95% ( = 3).

Product	Batch	Nonfucosylated (%)	Hybrid (%)	Sialylated (%)	Galactosylated (%)	High mannose (%)
MabThera	H0605	1.81 ± 0.04	5.00 ± 0.32	0.72 ± 0.08	43.34 ± 1.42	4.37 ± 0.42
	N3518	1.69 ± 0.11	3.48 ± 0.24	0.98 ± 0.22	46.21 ± 1.54	3.19 ± 0.54
	B62222	1.89 ± 0.11	2.91 ± 0.18	0.82 ± 0.12	45.58 ± 0.47	3.03 ± 0.17
Kikuzubam	5445130608	0.65 ± 0.21	2.72 ± 0.39	0.80 ± 0.21	57.08 ± 8.52	3.25 ± 0.43
	5445131216	0.65 ± 0.21	2.80 ± 0.08	0.71 ± 0.13	56.35 ± 0.64	3.31 ± 0.16
	5445131015	0.67 ± 0.05	3.19 ± 0.25	0.77 ± 0.13	54.26 ± 3.02	3.51 ± 0.23